David Lanfear M.D. M.S.

DL pic
Phone: (313) 874-5454
Fax: (313) 874-7137

Recent publications

Brewer RJ, Lanfear DE, Sai-Sudhakar CB, Sundareswaran KS, RaviY, Farrar DJ, Slaughter MS. Extremes of body mass index do not impact mid-term survival after continuous flow left ventricular assist device implantation. J Heart Lung Transplant 2012 Feb;31(2):167-72. PMID: 22305378

Jennings DL, Jones MC, Lanfear DE. Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devices. Int J Artif Organs 2012 Mar;35(3):177-9. PMID: 22461112

Lanfear DE, Hrobowski TN, Peterson EL, Wells KE, Swadia TV, Spertus JA, Williams LK. Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail 2012 Mar 1;5(2):202-8. PMID: 22260944

Singh G, Peterson EL, Wells K, Williams LK, Lanfear DE. Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure. J Cardiovasc Med 2012 Apr;13(4):246-53. PMID: 22343264

Morgan JA, Paone G, Nemeh HW, Henry SE, Gurlach BWilliams CT, Lanfear DE, Tita C, Brewer RJ. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2012 Jul;31(7):715-8. PMID: 22425231

Morgan JA, Paone G, Nemeh HW, Henry SE, Gerlach B, Williams CT, Lanfear DE, Tita C, Brewer RJ. Non-cardiac surgery in patients on long-term left ventricular assist device support. J Heart Lung Transplant 2012 Jul;31(7):757-63. PMID: 22425233

Cresci S, Dorn GW, Jones PG, Beitelshees AL, Li AY, Spertus JA, Lanfear DE. Adrenergic-pathway gene variants influence β-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol 2012 Sep 4;60(10):898-907. PMID: 22703928

Kumar R, Williams LK, Kato A, Peterson EL, Favoreto S Jr, Hulse K, Wang D, Beckman K, Thyne S, Lenoir M, Meade K, Lanfear DE, Levin AM, Favro D, Yang JJ, Weiss K, Boushey HA, Grammer L, Avila PC, Burchard EG, Schleimer R. Genetic variation in B cell-activating factor of the TNF family (BAFF) and asthma exacerbations among African American subjects. J Allergy Clin Immunol 2012 Oct;130(4):996-9. PMID: 22728080

Morgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, Williams CT, Lanfear DE, Tita C, Brewer RJ. Management of aortic valve insufficiency in patients supported by long-term continuous flow left ventricular assist devices. Ann Thorac Surg 2012 Nov;94(5):1710-2. PMID: 23098948

Hayek S, Escaro FC, Sattar A, Gamalski S, Wells KE, Divine G, Ahmedani BK, Lanfear DE, Pladevall M, Williams LK. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 2012 Dec 4. pii: S0002-9149(12)02323-5. PMID: 23219178


David E. Lanfear, MD, MS, is member of the Advanced Heart Failure and Cardiac Transplantation section at the Henry Ford Heart and Vascular Institute in Detroit, MI. Dr. Lanfear earned his medical degree from the University of Michigan Medical School, with election to Alpha Omega Alpha Honor Medical Society. He then completed his internal medicine residency at Barnes-Jewish Hospital in St. Louis, and subsequently entered cardiovascular disease fellowship at Washington University in St. Louis. There he completed a prolonged fellowship with advanced training in Cardiac Transplantation as well as 2 years of dedicated research training of Dr. Howard L. McLeod, focusing on applied pharmacogenetics and genomics. Dr. Lanfear successfully spearheaded several projects during this period, publishing several first-author manuscripts in high impact journals including the Journal of the American Medical Association (JAMA) and the Journal of the American College of Cardiology. Highlighting the importance of this work is the fact that the American Heart Association chose his JAMA work, titled "β2-Adrenergic Receptor Genotype and Survival among Patients Receiving β-Blocker Therapy after an Acute Coronary Syndrome" , as one of the top ten achievements of the year. He also received several awards recognizing his early career success including the Burton Sobel award for excellence in cardiovascular research at Washington University, and being a finalist for Jay Cohn Young Investigator award through the Heart Failure Society of America.

Dr. Lanfear has continued is research dedication and productivity, now with 19 publications, 18 published abstracts, and 3 manuscripts currently under consideration. This productivity has been rewarded by successfully obtaining funding from several sources including a Heart Failure Society of America Research Fellowship grant, an American Heart Association Scientist Development grant, multiple industrial grants, and finally in 2008 a Career Development Award from the National Institutes of Health. This grant continues Dr. Lanfear's Focus on pharmacogenetics and is titled "Pharmacogenetics of the B-type Natriuretic Peptide Pathway". Since joining Henry Ford Heart and Vascular Institute in 2005 Dr. Lanfear has underscored his dedication to research by completing a Masters degree in Clinical Research Design and Statistical Analysis from the University of Michigan, School of Public Health in 2007. This has enhanced his research skills and broadened his expertise. He has appointments in the Health Services Research division and as Assistant Professor at Wayne State University, reflecting his academic achievement and broad expertise. His development has been recognized externally as well and he has become highly involved in national academic societies. He is a Fellow of the American College of Cardiology (FACC), an active member of the ACC Heart Failure and Transplant committee, the Michigan ACC Chapter Council, as well as a member of the Heart Failure Society of America Research Committee. He is on the editorial board of the Journal of Cardiac Failure and has edited an issue of Heart Failure Reviews focused on cardiovascular pharmacogenetics.